Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Fecal Transplant Heals Colitis Caused by Immunotherapy
Anna Azvolinsky | Nov 12, 2018
A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive.
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
The Scientist Staff | Aug 22, 2018
Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.
Opinion: Learning from Immunotherapy’s Recent Failures
Luis Felipe Campesato | Aug 1, 2018
The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.
New Ovarian Cancer Vaccine Shows Promise
Catherine Offord | Apr 12, 2018
A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.
Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months
Catherine Offord | Dec 17, 2017
More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The Cancer Genes Needed for Immunotherapy Response
Anna Azvolinsky | Aug 7, 2017
Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.